Globus Medical Stock Plummets 22.96% Amid 129th Rank in Daily Market Volume

On May 9, 2025, Globus Medical (GMED) experienced a significant decline in its stock price, dropping by 22.96%. The trading volume for the day was substantial, reaching 6.15 billion, which placed it at the 129th position in the daily market rankings.

Globus Medical reported its first-quarter 2025 financial results, revealing a slight decrease in worldwide net sales to $598.1 million, a 1.4% decline compared to the same period last year. Despite this, the company achieved a GAAP net income of $75.5 million, marking a significant improvement from the previous year’s loss. The earnings report highlighted that U.S. net sales saw a modest increase of 0.2%, while international sales experienced a decline of 7.7%. The decrease in net sales was primarily attributed to fewer enabling technology unit sales. However, the company’s core U.S. spine business showed resilience, offsetting some of the challenges faced. Additionally, Globus Medical successfully returned to a debt-free status by paying off $450 million of debt from the NuVasive merger, and achieved record Q1 free cash flow.

The company also reported a GAAP diluted EPS of $0.54, a significant turnaround from a loss of $0.05 in the previous year. Non-GAAP diluted EPS rose to $0.68, reflecting an 8.5% increase. The improvement in net income was driven by reduced amortization costs and restructuring expenses. Furthermore, Globus Medical continues to invest in machinery and equipment to scale internal manufacturing, aiming for long-term sustainable growth.

Looking ahead, Globus Medical reaffirmed its full-year 2025 revenue guidance of $2.80 to $2.90 billion, while adjusting its non-GAAP EPS guidance to a range of $3.00 to $3.30. The company remains committed to its strategic objectives and confident in its ability to drive above-market revenue growth, focusing on delivering innovative solutions to enhance patient care.